Steven Cohen Bio Xcel Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.49 - $11.85 $595,829 - $2.84 Million	-239,289 Reduced 98.9%	2,669 $6,000
Q2 2023 Aug 14, 2023	BUY	$6.39 - $28.58 $1.55 Million - $6.92 Million	241,958 New	241,958 $1.61 Million
Q2 2022 Aug 15, 2022	SELL	$9.03 - $21.55 $730,527 - $1.74 Million	-80,900 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$15.0 - $22.83 $1.21 Million - $1.85 Million	80,900 New	80,900 $1.69 Million
Q1 2020 May 15, 2020	SELL	$12.26 - $41.14 $3.13 Million - $10.5 Million	-255,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$4.05 - $14.61 $182,250 - $657,450	45,000 Added 21.43%	255,000 $3.73 Million
Q3 2019 Nov 15, 2019	BUY	$7.04 - $11.77 $1.48 Million - $2.47 Million	210,000 New	210,000 $1.48 Million
Q4 2018 Feb 14, 2019	SELL	$2.41 - $7.61 $45,939 - $145,061	-19,062 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$7.51 - $12.99 $351,069 - $607,243	-46,747 Reduced 71.03%	19,062 $146,000
Q2 2018 Aug 14, 2018	BUY	$7.02 - $11.26 $44,633 - $71,591	6,358 Added 10.69%	65,809 $605,000
Q1 2018 May 15, 2018	BUY	$9.83 - $11.03 $584,403 - $655,744	59,451 New	59,451 $609,000

3.14M

22.2K

40.2K

Ticker BTAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,022,500
Market Cap $9.81M
Description
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.